Medication reconciliation is a critical process during transitions of care to prevent medication errors, adverse drug events, and unnecessary hospitalizations. This review synthesizes recent evidence and best-practice guidelines for performing medication reconciliation at key transition points, emphasizing the mechanisms, risk factors, and clinical implications. The article is geared towards doctors and healthcare professionals seeking to implement effective reconciliation protocols, reduce harm, and optimize pharmacotherapy during care transitions.
Transitions in patient care—such as admission, transfer, or discharge—are vulnerable periods rife with the potential for medication discrepancies. Medication reconciliation, a systematic process of creating the most accurate list of a patient’s current medicines and comparing it to the physician’s orders, is essential to ensure patient safety and continuity of care. Failure in this process can result in adverse drug events (ADEs), making medication reconciliation a patient safety priority as emphasized by agencies like the Joint Commission and WHO.
Studies reveal that up to 60% of medication errors occur during transitions of care, with 20% leading to patient harm. Adverse drug events are responsible for nearly 700,000 emergency department visits and 100,000 hospitalizations annually in the United States alone. Elderly patients and those with polypharmacy are disproportionately affected. The prevalence of discrepancies ranges from 20–80% during hospital admissions and up to 40% during discharge, underscoring the urgent need for robust medication reconciliation practices.
The pathophysiology underlying medication-related harm at transitions stems from the breakdown in communication among patients, caregivers, and healthcare providers. Unintentional omission, duplication, dosing errors, and drug-drug interactions can occur when medication histories are incomplete or inaccurately transcribed. Cognitive overload, time constraints, and fragmented health information systems exacerbate these risks, leading to preventable ADEs and patient morbidity.
High-risk populations include older adults, individuals on complex medication regimens (polypharmacy), patients with multiple comorbidities, those with cognitive impairment, and patients transitioning between multiple care settings (hospital, rehabilitation, nursing home). Additional risk factors encompass language barriers, low health literacy, and lack of a consistent primary care provider. Institutional factors such as poor interprofessional communication and inadequate electronic health record integration also contribute to increased risk.
Medication errors at transitions may manifest as acute clinical deterioration, unexplained laboratory abnormalities, or new-onset symptoms such as confusion, hypotension, or bleeding. Subtle features such as therapeutic failure or exacerbation of chronic disease may also indicate reconciliation lapses. Early recognition is vital for prompt intervention and mitigation of harm.
Diagnosis involves meticulous review of the patient’s medication regimen, including prescription, over-the-counter, herbal, and supplement use. Cross-referencing medication lists from various sources—patient interviews, pharmacy records, and previous medical documentation—is crucial. Discrepancies are identified via structured tools or checklists, with root-cause analysis applied to any adverse outcomes or near-misses to refine the reconciliation process.
Effective management hinges on a standardized, multidisciplinary approach. Pharmacists, nurses, and physicians must collaborate to obtain a Best Possible Medication History (BPMH), verify accuracy at each transition point, and resolve discrepancies before care is handed over. Patient education, clear documentation, and communication with community care providers are integral components. Technology, such as integrated electronic health records with medication reconciliation modules, enhances accuracy and efficiency.
Recent advances include the adoption of clinical decision support systems (CDSS) that flag potential interactions or duplications, and the use of mobile applications enabling patients to maintain up-to-date medication lists. Automated alerts and real-time data sharing between hospital and community pharmacies are increasingly being implemented. Pharmacogenomics is emerging as a tool to tailor medication regimens, particularly for high-risk drugs, further reducing the risk of ADEs during transitions.
International guidelines recommend a five-step medication reconciliation process: (1) develop a comprehensive medication list; (2) compare with current orders; (3) identify and resolve discrepancies; (4) communicate changes to patient and caregivers; (5) update records at every transition. The Joint Commission mandates medication reconciliation at every admission, transfer, and discharge. The Institute for Healthcare Improvement (IHI) and WHO stress the importance of leadership support, staff training, and performance measurement to ensure sustained improvement.
Medication reconciliation is a cornerstone of patient safety during transitions of care. Adhering to evidence-based guidelines, leveraging technology, and fostering interdisciplinary collaboration can significantly reduce medication errors and ADEs. Ongoing research into innovative tools and personalized medicine promises to further enhance the safety and efficacy of medication management at these critical junctures. Healthcare professionals must prioritize robust reconciliation processes to achieve optimal patient outcomes and minimize preventable harm.
1.
"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.
2.
Recently released national data on drug use and abuse among Americans.
3.
Despite Medicare Coverage, Cancer Genomic Testing Still Low
4.
Ketamine plus psychotherapy for "excellent" PTSD
5.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
1.
Personalized Tumor Ecological Landscapes in Oncology
2.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
3.
Preserving Social Identity During Cancer Survivorship
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Regenerative Models of Tumor Microenvironments: Clinical Relevance and Emerging Insights
1.
International Conference on Cancer Nursing and Rehabilitation Strategies
2.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
3.
International Conference on Innovations in Critical Care for Oncology and Cardiology
4.
International Symposium on Oncology, Cardiology and Critical Care Innovations
5.
International Conference on Cancer Nursing and Hematology Support
1.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
From Guidelines to Practice: Hematology
5.
Breast Cancer Awareness and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation